ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5152.98M
Enterprise Value 3239.04M
Trailing P/E N/A
Forward P/E 1-1.08
PEG Ratio (5 yr expected) 1-0.04
Price/Sales (ttm)0.50
Price/Book (mrq)0.28
Enterprise Value/Revenue 30.78
Enterprise Value/EBITDA 6-14.61

Trading Information

Stock Price History

Beta (3Y Monthly) 1.26
52-Week Change 3-89.13%
S&P500 52-Week Change 31.73%
52 Week High 329.7500
52 Week Low 32.2700
50-Day Moving Average 35.1549
200-Day Moving Average 310.0295

Share Statistics

Avg Vol (3 month) 31.32M
Avg Vol (10 day) 32.15M
Shares Outstanding 548.13M
Float 39.47M
% Held by Insiders 11.85%
% Held by Institutions 1112.32%
Shares Short (Jul 31, 2019) 414.16M
Short Ratio (Jul 31, 2019) 418.07
Short % of Float (Jul 31, 2019) 451.53%
Short % of Shares Outstanding (Jul 31, 2019) 429.43%
Shares Short (prior month Jun 28, 2019) 413.48M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -25.94%
Operating Margin (ttm)-11.78%

Management Effectiveness

Return on Assets (ttm)-1.84%
Return on Equity (ttm)-13.79%

Income Statement

Revenue (ttm)306.16M
Revenue Per Share (ttm)6.45
Quarterly Revenue Growth (yoy)-67.40%
Gross Profit (ttm)372.12M
EBITDA -16.36M
Net Income Avi to Common (ttm)-79.41M
Diluted EPS (ttm)-1.6740
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)296.89M
Total Cash Per Share (mrq)6.18
Total Debt (mrq)383.04M
Total Debt/Equity (mrq)70.30
Current Ratio (mrq)3.81
Book Value Per Share (mrq)11.47

Cash Flow Statement

Operating Cash Flow (ttm)-26.55M
Levered Free Cash Flow (ttm)-55.62M